Medical Condition News

RSS

Study provides guidelines on how to combine antiangiogenic drugs with nanotherapeutics

Combining two strategies designed to improve the results of cancer treatment - antiangiogenesis drugs and nanomedicines - may only be successful if the smallest nanomedicines are used. A new study from Massachusetts General Hospital (MGH) researchers, appearing in Nature Nanotechnology, finds that normalizing blood vessels within tumors, which improves the delivery of standard chemotherapy drugs, can block the delivery of larger nanotherapy molecules.

10 Apr 2012

Special issue focuses on costs, benefits and hope inspired by cancer care

A new analysis provides a closer look at how much cancer patients value hope - with important implications for how insurers value treatment, particularly in end-of-life care.

10 Apr 2012

HeadCase may be safe and effective for trauma victims

Undergraduate students at Rice University have come up with what they hope will prove to be a better and safer version of cervical collars to stabilize the heads and necks of accident victims. Cervical collars have been in common use since their introduction during the Vietnam War.

10 Apr 2012

Changes in corneal thickness occur in patients at early stages of FECD

A national consortium of researchers has published new findings that could change the standard of practice for those treating Fuchs' Endothelial Corneal Dystrophy (FECD), a disease characterized by cornea swelling that can eventually lead to the need for corneal transplantation.

10 Apr 2012

Study finds successful weight loss strategies for obese people

A third of Americans are now obese, and up to 70% of them are trying to lose weight. In a new study published in the American Journal of Preventive Medicine, researchers from Harvard Medical School and Beth Israel Deaconess Medical Center in Boston have found in a nationally representative sample that obese dieters who said they ate less fat, exercised more, and used prescription weight loss medications were more likely to lose weight.

10 Apr 2012

FDA grants Fast Track designation to EpiCept's AmiKet

EpiCept Corporation announced today that AmiKet (amitriptyline 4%, ketamine 2% cream) has been granted Fast Track designation by the U.S. Food and Drug Administration.

10 Apr 2012

Regular dental x-rays increase risk of meningioma in the U.S.

People who received frequent dental x-rays in the past have an increased risk of developing the most commonly diagnosed primary brain tumor in the United States. That is the finding of a study published early online in Cancer, a peer-reviewed journal of the American Cancer Society.

10 Apr 2012

Proteonomix provides corporate and clinical trial updates

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today provided updates on its progress.

10 Apr 2012

Higher blood glucose levels may improve survival rates for heart failure patients with diabetes

Lowering glucose levels for people with diabetes is normally critical to improving health outcomes. But for those with heart failure, that might not always be the case, say UCLA researchers.

10 Apr 2012

KLF15 gene governs the body's ability to burn fat during exercise

While exercise is accepted universally as the most beneficial prescription physicians can write for patients, little is known about the molecular mechanisms that generate its widespread health benefits. Researchers from Case Western Reserve School of Medicine have shed light on this mystery by discovering that a genetic factor, Kruppel-like Factor 15 (KLF15), governs the body's ability to burn fat during exercise.

10 Apr 2012

Three ESRD products chosen for FDA's Innovation Pathway program

Three products for patients with end stage renal disease (ESRD) have been chosen to participate in the FDA's Innovation Pathway, an evolving system designed to help medical devices reach patients in a safe, timely and collaborative manner.

10 Apr 2012

RegeneRx wins four patents in Israel, Mexico

RegeneRx Biopharmaceuticals, Inc. announced today that the Company has received an issued patent in Mexico and allowances of three additional patent applications in Mexico and Israel.

10 Apr 2012

ReCor Medical provides updated data from REDUCE Percutaneous Renal Denervation System study

ReCor Medical, an emerging medical device company, disclosed today updated data for the REDUCE First-In-Man clinical study of its PARADISE (Percutaneous Renal Denervation System) ultrasound platform for achieving renal denervation.

10 Apr 2012

Monitoring necessary for early intervention in Fuchs' Endothelial Corneal Dystrophy patients

10 Apr 2012

OphthaliX completes CF101 preclinical studies on Anterior Uveitis

OphthaliX announced today the completion of preclinical studies, showing that its CF101 drug candidate is efficacious in treating Anterior Uveitis

10 Apr 2012

Aristolochic acid exposure leads to kidney failure and UUC

Aristolochic acid (AA), a component of a plant used in herbal remedies since ancient times, leads to kidney failure and upper urinary tract cancer (UUC) in individuals exposed to the toxin.

10 Apr 2012

Dementia sufferers and caregivers unhappy with quality of care

Dementia patients and their families have been asked to assess the quality of care available to them. Their reports are far from satisfactory. Alzheimer's Australia says dementia patients and their carers are being let down right across the health system. The Federal Government has promised to use the report to help decide how to improve the system.

9 Apr 2012

Berries may reduce Parkinson’s disease risk in men: Study

A new study has found that men who regularly consume foods rich in flavonoids, such as berries, apples, certain vegetables, tea and red wine, may significantly reduce their risk for developing Parkinson's disease. The study was published in the journal Neurology this week. It added that there was no such effect among women.

9 Apr 2012

FDA approves scan to detect Alzheimer’s disease early

The test uses a chemical called florbetapir, known by the brand name Amyvid, which is a radioactive agent that tags clumps of a sticky substance called an amyloid. Amyloid proteins are hallmarks of Alzheimer's disease. The chemical, which costs $1,600 per dose, then is detected using a brain imaging technique called positron emission tomography, known as PET scans. For patients who already have some symptoms of cognitive decline, a positive scan suggests that moderate to frequent amyloid plaques are present in the brain, which is consistent with Alzheimer's disease.

9 Apr 2012

Stealth announces results from three Bendavia Phase I clinical trials for mitochondrial dysfunction

Stealth Peptides Inc., a privately held biopharmaceutical company developing innovative therapies for diseases with unmet medical needs, announced today the results from three Phase I clinical trials of Bendavia, a novel compound that targets the mitochondrion to treat mitochondrial dysfunction, including ischemia reperfusion and microvascular injury.

9 Apr 2012